*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Cosmos Health Inc. (NASDAQ: COSM)
COSM is our brand new NASDAQ high growth alert.
Trading at just around 0.20, COSM has a chart setup positioning for a big breakout opportunity with a history of very large moves in a short period of time.
In addition, COSM announced multiple accomplishments in the past two weeks that could be big growth catalysts.
COSM is a NASDAQ listed “diversified, vertically integrated global healthcare group”.
COSM owns a “portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.”
COSM “set a new all-time revenue record of $65.3 million, up 20% year-over-year — the highest annual revenue in Company history.” – for “FY2025”.
“Gross profit surged 83% to $7.9 million, with gross margin expanding 418 basis points to 12.1%.”
Furthermore:
“Carrying that record momentum forward, Q1 2026 delivered revenue of $17.9 million — up 31% year-over-year. On an adjusted basis, revenue reached $18.4 million, up 34% year-over-year.”
COSM “expects to surpass $90 million in revenue in FY2026, representing approximately 38% year-over-year growth — the sharpest annual growth rate in Company history and a clear signal that Cosmos Health has entered a new phase of above-average expansion.”
Through its “subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union”.
COSM also “distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK”.
Furthermore, the Company has “established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products”.
COSM has also “entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA”.
With a global distribution platform, COSM is currently “expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.”
COSM has announced many big growth catalysts just in the past two weeks.
Last week, the company announced:
“Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657”
Greg Siokas, CEO of Cosmos Health, stated:
“The successful testing of C-Scrub Wash 4% under EN 1656 and EN 1657 represents an important milestone as we extend a brand we have already established in the human healthcare market into the fast-growing veterinary sector. This marks Cosmos Health's first entry into animal health, and we believe that combining existing C-Scrub brand awareness, manufacturing capabilities, and distribution infrastructure positions us to pursue meaningful commercial opportunities globally.”
In addition, the company also announced:
“Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline”
“Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%”
“Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 million”
“Capital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilution”
“Real Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization”
“Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million from internally generated cash flow”
Plus, the company also announced:
“Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value”
“Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 million”
“Proceeds could fund a meaningful acquisition or eliminate debt entirely”
“Company remains fully committed to its core healthcare operations”
In addition, last Thursday, the company announced:
“Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz”
Greg Siokas, CEO of Cosmos Health, stated:
"The expansion of Sky Premium Life across all 27 EU Member States through Skroutz represents a key milestone in our international growth strategy. By leveraging Skroutz’s cross-border infrastructure, we are able to efficiently scale distribution and reach consumers across Europe. This initiative further enhances our brand visibility and supports our continued focus on driving revenue growth and expanding our global presence.”
Last Friday, the company announced:
“Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories”
“Science-backed, USDA and EU-certified, whole olive tree supplement for two major wellness categories — rapidly growing global market projected to exceed $33 billion”
Here are some of the highlights from this press release:
“Oliv18™ expands the 18 Series with a USDA and EU organic certified, 100% solvent-free, whole olive polyphenol formulation from the Moroccan Saharan desert
“Hydroxytyrosol — the key active in Oliv18™ — is the highest ORAC polyphenol”
“A single 250 mg daily dose meets EFSA's 5 mg/day hydroxytyrosol minimum dose for protection against LDL oxidation”
“A single daily dose equivalent to approximately 11 teaspoons of good quality extra virgin olive oil — compared to an average of half a teaspoon per day in the U.S.”
“Targeting the multibillion cardiovascular health and antioxidant markets, initially in the United States and globally thereafter — within a combined global market landscape projected to exceed $33 billion by 2035”
On Monday, the company announced:
“Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives”
Here are the highlights from this press release:
“Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent application WO2025108566A1 from Cloudpharm P.C.”
“Patent protection being pursued at national and regional levels across key international markets”
“Technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development”
“Expands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilities”
“Aligned with the Company's broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value”
Greg Siokas, CEO of Cosmos Health, stated:
“This acquisition further strengthens our transition from AI-enabled discovery to proprietary product development and commercialization. By combining intellectual property, advanced formulation technologies, nanotechnology expertise, and our manufacturing infrastructure, we continue to build a scalable innovation platform designed to create long-term shareholder value.”
On Tuesday, the company announced:
“Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN”
Greg Siokas, CEO of Cosmos Health, stated:
"Cana's contract manufacturing division is a core pillar of our long-term growth strategy, generating high-margin, recurring revenue with strong cash flow visibility through multi-year agreements with established partners such as Provident. Each new order builds a stable, predictable revenue base, while diversifying our order book across multiple products and therapeutic areas — from central nervous system to musculoskeletal, vitamin, and anti-inflammatory categories. By continuing to upgrade and modernize our European GMP-certified infrastructure and capacity, we are well-positioned to keep securing new contracts and accelerate the growth of this high-margin segment.”
On Wednesday, the company announced:
“Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway”
Key Highlights
“Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2.”
“Record operational momentum: CosmoFarm wholesale distribution and GMP-certified Cana contract manufacturing both delivering record volumes.”
“Guidance signaling potential financial transformation: targeting over $200M revenue, $44.2M Adjusted EBITDA, and $92.3M stockholders' equity by 2029.”
“Global brand momentum: Sky Premium Life, 18 Series, and C-Scrub scaling from Europe and the Middle East to the U.S., with C-Scrub now extending into the global animal health industry.”
“Advancing R&D pipeline: spanning oncology, neurology, and inflammation, supported by our AI-driven Cloudscreen platform and nanotechnology investments.”
“CCX0722 — Obesity: proprietary weight-management product in final development phase, targeting a global market projected to reach ~$299Bn by 2030.”
“Landmark financing: pursuing a financing program of up to €25M with the European Investment Bank.”
“U.S. market entry active and generating revenue: local manufacturing, with projected annualized revenue, including Noor18, exceeding $20M at ~75% gross margins within 12–18 months.”
“Strength through diversification: a vertically integrated platform spanning distribution, contract manufacturing, proprietary brands, and R&D, with ~$20M in non-core assets identified to unlock value.”
“CEO commitment, aligned with shareholders: continued insider share purchases, reflecting management's conviction in the long-term value being created.”
In addition, the company also announced:
“Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries”
“Under the agreement, Cana will manufacture 1.3 million units annually of VASCLOR® GEST (progesterone) 400mg vaginal pessaries, or a total of 3.9 million units over the three-year period, indicated for luteal phase support and as part of assisted reproduction treatment. The product is supplied as 400mg per pessary in boxes of 15 pessaries (in PVC-PE strips).”
“This agreement broadens Cana's contract manufacturing customer base and expands its capabilities into women's health and reproductive medicine. Verisfield, which began operations in 2000, markets a portfolio of more than 60 pharmaceutical products across seven therapeutic categories in Greece and internationally through strategic partners.”
Greg Siokas, CEO of Cosmos Health, stated:
"We are delighted to welcome Verisfield as a new contract manufacturing partner for Cana. This agreement marks a further expansion of our high-margin contract manufacturing division and diversifies our order book across additional customers and therapeutic areas, including women's health. By continuing to upgrade our European GMP-certified infrastructure and capacity, we are well-positioned to keep securing new contracts and accelerate the growth of this important segment.”
Most recently, yesterday, the company announced big breaking news:
“Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio”
Here are the highlights from this press release:
“Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit.”
“Immediately accretive: expected to support margin expansion, profitability, and cash flow.”
“Deepens vertical integration: expected to drive synergies, optimized production, economies of scale, expanded capacity, and a strengthened R&D engine.”
“State-of-the-art production plant: GMP-licensed, approximately 59,000 square feet, built to the highest European standards, providing a clear growth avenue.”
“Manufacturing excellence: a broad range of dosage forms, certified to GMP, ISO, Kosher, and Halal standards, with site registrations for the UAE, Qatar, Iraq and Lebanon.”
“Boosts product portfolio: adds advanced and branded generics and OTC pharmaceutical products to the Cosmos Health portfolio.”
We believe COSM could be positioned for significant upside.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 6/11/26 for the distribution of this advertisement about COSM dated 6/12/26. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 10/1/25 for the distribution of a prior advertisement about COSM. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.